Debbie Hay

From Wikipedia, the free encyclopedia

Debbie Hay
Born
Deborah Lucy Hay
Alma materImperial College London
Scientific career
Fieldsmolecular pharmacology
Institutions
Thesis

Deborah Lucy Hay FRSNZ is a New Zealand academic.[1] In 2022, she was elected a Fellow of the Royal Society Te Apārangi.

Academic career[edit]

After an undergraduate in pharmacology at the University of Sheffield, Hay did a PhD in molecular pharmacology entitled 'Investigation of the calcitonin receptor-like receptor and receptor activity modifying proteins' at Imperial College London. Hay moved to the University of Auckland, where she rose to full professor. She is now a full professor at the University of Otago and is a Fellow of the British Pharmacological Society.

Her research involves molecular pharmacological techniques[2] to investigate phenomenon such as migraines.[3][4] In 2016 she was awarded a James Cook Research Fellowship to investigate the causes and potential new treatments for migraines.[5]

In 2022, Hay was elected a Fellow of the Royal Society Te Apārangi. The society said "Professor Debbie Hay is an innovative molecular pharmacologist whose seminal contributions have enhanced understanding of the roles of G protein-coupled receptors (GPCRs) in conditions such as migraine, diabetes and obesity... ...she has established herself as a world leader in a complex field, in high demand internationally as a collaborator, speaker, writer and consultant to industry."[6]

Selected works[edit]

  • Bailey RJ, Walker CS, Ferner AH, Loomes KM, Prijic G, Halim A, Whiting L, Phillips AR, Hay DL. "Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes." Br J Pharmacol 2012 May;166(1):151-67.
  • Bailey RJ, Hay DL. "Agonist-dependent consequences of proline to alanine substitution in the transmembrane helices of the calcitonin receptor." Br J Pharmacol. 2007 Jul;151(5):678-87.
  • Dakin, C. L., I. Gunn, C. J. Small, C. M. B. Edwards, D. L. Hay, D. M. Smith, M. A. Ghatei, and S. R. Bloom. "Oxyntomodulin inhibits food intake in the rat." Endocrinology 142, no. 10 (2001): 4244–4250.
  • Hay, Debbie L., David R. Poyner, and Patrick M. Sexton. "GPCR modulation by RAMPs." Pharmacology & Therapeutics 109, no. 1 (2006): 173–197.
  • Hay, Debbie L., George Christopoulos, Arthur Christopoulos, David R. Poyner, and Patrick M. Sexton. "Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes." Molecular Pharmacology 67, no. 5 (2005): 1655–1665.
  • Hay, Debbie L., Stephen G. Howitt, Alex C. Conner, Marcus Schindler, David M. Smith, and David R. Poyner. "CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22–52, CGRP8–37 and BIBN4096BS." British Journal of Pharmacology 140, no. 3 (2003): 477–486.
  • Walker, Christopher S., Alex C. Conner, David R. Poyner, and Debbie L. Hay. "Regulation of signal transduction by calcitonin gene-related peptide receptors." Trends in Pharmacological Sciences 31, no. 10 (2010): 476–483.

References[edit]

  1. ^ "Professor Debbie Hay - The University of Auckland". Unidirectory.auckland.ac.nz. Retrieved 4 January 2018.
  2. ^ "University of Auckland celebrates Marsden fund success | Scoop News". Scoop.co.nz. 3 November 2016. Retrieved 4 January 2018.
  3. ^ "Pain relief: New Zealand's breakthrough in migraine treatment". The New Zealand Herald. 9 March 2015. Retrieved 4 January 2018.
  4. ^ Ceinwen Curtis - ceinwen.curtis@radionz.co.nz (10 April 2015). "Research offers migraine treatment hope | Radio New Zealand News". Radionz.co.nz. Retrieved 4 January 2018.
  5. ^ "Search James Cook Fellowship awards 1996–2017". Royal Society Te Apārangi. Retrieved 28 October 2023.
  6. ^ "Researchers and scholars at the top of their fields elected as Fellows". Royal Society Te Apārangi. Retrieved 18 March 2022.

External links[edit]